All In Biotech

Drug Trial Radar · NCT05636215

A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

368

Planned (sponsor's estimate)

Start

Apr 4, 2023

Primary completion

Apr 30, 2025

Study completion Oct 31, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of IBI354 (study drug), and to explore and confirm the efficacy, safety and tolerability of IBI354 in subjects with locally advanced unresectable or metastatic solid tumors.

Conditions

  • Locally Advanced Unresectable or Metastatic Solid Tumors

Interventions

  • IBI354Biological

    Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of serious adverse events (SAEs), treatment-emergent AEs (TEAEs).Time frame: Up to 30 days after the last administration
  2. Number of dose-limiting toxicity (DLT)Time frame: 21 days during the first cycle in Phase Ia

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, Australia · Completed

  • Westmead Hospital

    Sydney, New South Wales, Australia · Completed

  • Sunshine Coast University Private Hospital

    Sunshine Coast, Queensland, Australia · Completed

  • Monash Health

    Clayton, Victoria, Australia · Completed

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Affiliated Cancer Hospital of Chongqing University

    Chongqing, Chongqing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.